|
Pardoprunox (INN) (code name SLV-308) is an antiparkinsonian drug currently under development by Solvay for the treatment of Parkinson's disease and as of March 2010 is in Phase III clinical trials. It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned.〔 Pardoprunox acts as a D2 (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT1A receptor (pKi = 8.5) full agonist (IA = 100%).〔 It also binds to D4 (pKi = 7.8), α1-adrenergic (pKi = 7.8), α2-adrenergic (pKi = 7.4), and 5-HT7 receptors (pKi = 7.2) with lower affinity.〔〔 Relative to other dopaminergic antiparkinsonian agents, pardoprunox is thought to have significantly less of a propensity for inducing certain side effects like dyskinesia and psychosis.〔 ==See also== * Aripiprazole * Bifeprunox * Pimavanserin 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Pardoprunox」の詳細全文を読む スポンサード リンク
|